WHO ICTRP trial
A randomized, double-blind, parallel-group, active-controlled, multi-center…
PER-046-14 · Registro Peruano de Ensayos Clínicos (REPEC)
Key facts
| Trial ID | PER-046-14 |
|---|---|
| Public title | A randomized, double-blind, parallel-group, active-controlled, multi-center study to evaluate the long-term safety and efficacy of combination of solifenacin succinate with mirabegron compared to solifenacin succinate and mirabegron in subjects with overactive bladder |
| Scientific title | A randomized, double-blind, parallel-group, active-controlled, multi-center study to evaluate the long-term safety and efficacy of combination of solifenacin succinate with mirabegron compared to solifenacin succinate and mirabegron in subjects with overactive bladder |
| Primary sponsor | Astellas Pharma Europe B.V, |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Study type | Interventional |
| Phase | III |
| Countries | Poland;United Kindgdom;China;Korea South;Philippines;Indonesia;Japan;Malasya;Singapore;Thailand;Taiwan;Turkey;Germany;Ivory… |
| Conditions | -N31 ;N31 |
| Interventions | Pharmaceutical form: - Solifenacin / Solifenacin placebo: 5mg tablets - Mirabegron / Mirabegron Placebo: 50mg tablets Dose and frequency: during the study, the subject will take 2 tablets once daily, in the morning. Adminsitration route… |
| Registration date | Oct 17, 2014 |
| Target size | 70 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: